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Introduction: The prognostic role of epidermal growth factor re-
ceptor (EGFR) mutations in patients with surgically resectable
non-small cell lung cancer (NSCLC) without EGFR tyrosine kinase
inhibitor treatment has not been well established, because the reports
are still few.
Materials and Methods: We analyzed the survival data of 164
patients with surgically resectable (stages I to IIIA) NSCLC of two
year groups (1996–1998 and 2002–2004), and compared with
EGFR mutations, KRAS mutations, and EGFR gene copy numbers.
Results: Comparing the survival of wild-type patients and patients
having L858R mutations or exon 19 deletion, the median survival
was much longer for patient with EGFR mutations (54.7 months)
than wild type (34.9 months). The difference was not statistically
significant by univariate analysis (p  0.1981) but had borderline
significance by multivariate analyses (p  0.0506). In addition, the
3-year survival rates of patients with EGFR mutations were also
significantly higher than wild type (p  0.0232). After exclusion of
18 patients treated by EGFR-tyrosine kinase inhibitor for tumor
recurrence, the trends were still the same. Patients with KRAS
mutations had shorter median survival (21 months) than wild type
(44.4 months). Patients with EGFR polysomy (copies) also had
longer median survival (56.2 months) than wild type (53.4 months).
But the survival differences of these two genetic markers were all
not significant statistically.
Conclusion: It is intriguing that patients with NSCLC with EGFR
mutations had better survival than wild type. Such a tumor biology
may confound the survival data in a study without the stratification
by EGFR mutation.
Key Words: EGFR, KRAS, Lung cancer, Mutation, Survival, Copy
number, Chemotherapy.
(J Thorac Oncol. 2010;5: 1175–1184)
Lung cancer, especially non-small cell lung cancer (NSCLC),has become the leading cause of cancer death in most part of
the world because of its high mortality rate and poor response to
treatment.1,2 Thus, it has become the leading target for the
development of new anticancer drugs. Because conventional
chemotherapy (C/T) regimens seemed to have limited efficacy
for advanced-staged NSCLC,3 new therapeutic agents, espe-
cially targeted therapy by inhibition of activated oncoprotein
kinases, has become a popular approach.4,5 Among them, the
epidermal growth factor receptor (EGFR) tyrosine kinase inhib-
itors (TKIs) have achieved rapid and good therapeutic response
for the treatment of NSCLC.6,7 The significantly higher response
rate noted in Japanese patients than in a predominantly Europe-
an-derived population (27.5% versus 10.4%) in two clinical
trials, 8,9 has lead to the identification of EGFR mutations, which
are correlated with the clinical responsiveness, by Lynch et al.10
and Paez et al.11 All of these mutations were within exon 18
through 21 of the kinase domain (KD) of EGFR and most were
identified in adenocarcinoma (ADC).10–14 These mutations can
cause constitutive activation of EGFR protein and confer sus-
ceptibility to TKIs.10–12,15
For patients with advanced-staged NSCLC with EGFR
mutations, in addition to the benefit from TKI treatment and
longer survival,16 two phase III clinical trials for patients with
NSCLC (TRIBUTE and Iressa Pan-Asia Study (IPASS), the
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former patients from United States, and the latter from Asian
countries, respectively), also have shown a higher response
rate to C/T for patients with EGFR mutation than wild
type.17,18 But the study by Cappuzzo et al.19 (patients from
Italy) did not show such difference. Therefore, the prognostic
value of EGFR mutations for patients with advanced-staged
NSCLC without TKI treatment remained controversial.
The prognostic role of EGFR mutations in patients with
resectable NSCLC also has not been well established, be-
cause the reports are still quite few. Three earlier studies on
the overall survival of patients with NSCLC without TKI
treatment have reported that there was no significant differ-
ence between wild-type and EGFR mutations.14,20,21 The
study by Marks et al.22 was the first to suggest a better
prognostic role for EGFR mutations. They reported a higher
3-year survival rate for patients with resectable ADC (stages
I to IIIa) with EGFR mutations than KRAS mutations. The
latter was well known as a poor prognostic indicator.23,24
However, due to short follow-up time, they could not dem-
onstrate a significant difference in the overall survival after
adjustment with tumor stages. Recently, Kosaka et al.25 also
reported a similar study on the prognostic implications of
EGFR mutations in a large cohort of Japanese patients with
surgically treated lung ADC. Although they also found a
significant longer overall survival for patients with EGFR
mutations compared with wild type by univariate analyses,
the difference became insignificant by multivariate analyses.
We have previously reported a high EGFR mutation
rate (38.6%) and very low KRAS mutation rate (3.8%) in
surgically treated patients with NSCLC in Taiwan.13,26 We
were also quite interested in the prognostic significance of
EGFR mutation in these patients. Because all of the patients
with surgical resectable NSCLC (stages I to IIIa) in our
published study series received operations 5 years
ago,13,26,27 the follow-up time was long enough for evaluation
of their overall survival. Thus, we have performed a retro-
spective study of the prognostic roles of three molecular
markers, including EGFR mutation, KRAS mutation, and
EGFR gene copy number, on the survival of our patients with
surgically resectable NSCLC.
PATIENTS AND METHODS
Patient Samples
Fresh-frozen tumor specimens from patients received
surgical resection and with signed informed consent at
Chang-Gung Memorial Hospital for NSCLC from January
1996 to December 1998, and from May 2002 to May 2004,
were obtained from the tissue bank of Chang-Gung Memorial
Hospital. All specimens were snap frozen soon after resection
and stored at 80°C. The patients from May 2002 to May
2004 were the patient group of our first EGFR mutation
study.13 The specimens from 1996 to 1998 were a retrospec-
tive application for the earliest fresh-frozen tumor tissue of
the tissue bank, mainly to study the genetic markers and
survival of NSCLC of earlier years for comparison. We did
not apply more surgical specimens from January 1999 to
April 2002 from the tissue bank because of limitation of
research manpower. The study protocol had been reviewed
and approved by the Institutional Review Board of Chang-
Gung Memorial Hospital and National Health Research In-
stitutes. Patients of stage IIIb or IV disease were excluded for
this study. Thus, totally 168 patients were included (70
patients operated from January 1996 to December 1998, and
98 patients operated from May 2002 to May 2004). The
therapeutic protocol and the surgical procedures of these
patients were all similar. More than 90% of the patients were
operated by the same surgeon (H-P.L.). For stage I patients,
no adjuvant therapy was given. Most stage II and stage IIIa
patients received postoperative radiotherapy (R/T). A few pa-
tients received neoadjuvant or adjuvant C/T. All clinicopatho-
logical information was obtained from the medical records.
The stage data listed is pathology stage according to Amer-
ican Joint Committee on Cancer guidelines. Smoking status is
defined as nonsmokers (never smoke or 100 lifetime ciga-
rettes) and ever smokers. Date of death was obtained from the
cancer registration data of Chang-Gung Memorial Hospital or
the government’s records from Department of Health of
Taiwan up to year 2007. Overall survival was from the date
of surgery until death.
EGFR and KRAS Mutation Analyses and EGFR
Gene Copy Number Detection
DNA extraction from fresh-frozen tumor tissue was per-
formed according to the protocol as mentioned previously.13 For
EGFR mutation, coding sequences from exons 18 to 21 were
amplified and subjected to direct sequencing. For analysis of the
KRAS mutation, coding sequences of exons 2 and 3 were
amplified and subjected to direct sequencing. Determina-
tion of EGFR gene copy number was performed by chro-
mogenic in situ hybridization (CISH) on paraffin sections
of the tumor tissue. The tumor was considered to be CISH
positive if the EGFR gene copy number was 5 signals
per nucleus in 40% of tumor cells. The methodology of
the above three studies were the same as mentioned pre-
viously.13,26,27 The EGFR mutation and KRAS mutation
analyses were performed and successful in 158 and 156
patients, respectively. The EGFR gene copy number by
CISH was performed in 134 patients and successful in 124
patients (CISH study failed in 10 cases. One from the
patients received surgery during 2002–2004, and nine from
the patients received surgery in 1996, mainly due to
degradation of the DNA in the paraffin block). The data of
EGFR mutation, KRAS mutation, and EGFR gene copy
number of these patients have been included in our three
published study series, respectively.13,26,27
Statistical Analysis
To examine the differences in the major clinicopatho-
logical features and molecular markers, frequencies and pro-
portions are compared by conventional 2 association test or
Fisher’s exact test (when there is at least a cell frequency
5). For specific subgroups defined by different covariates,
we report the median survival estimates with corresponding
95% confidence intervals. The differences in overall survivals
are checked by log-rank tests. If the survival comparison
focused on a fixed time point (such as 3 year- or 5-year
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survivals), a method offered in Klein et al.28 is used. The test
statistic denoted X2
2 therein is:
Sˆ 1
2tSˆ 2
2t{log Sˆ 1t log Sˆ 2t}
2
Sˆ 2
2tˆ Sˆ 1
2
 Sˆ 1
2tˆ Sˆ 2
2
.
The X2
2 statistic is distributed as a 2 distribution on one
degree of freedom. This is in particular meaningful when the
overall survival of a group is not apparently superior to that
of the other group, but benefit has appeared at an earlier time
period in the therapeutic process. Multivariate analysis of
overall survival was performed using Cox’s regression model
and use stratified analysis to deal with the stratification effect.
Multiple-comparison step-down Holm-Bonferroni ad-
justments were also made.
RESULTS
Of the 168 patients originally included in this study,
two patients died of surgical complications and two patients
died of other causes were excluded for survival analysis.
Thus, a total of 164 patients were included for this study.
Because the nonsurgical treatments for NSCLC have much
improvement in recent years, we have divided these patients
in two year groups: year group 1 (69 patients for 1996–1998)
and year group 2 (95 patients for 2002 –2004), so that we
could also evaluate the impact of treatment improvement. All
patients, except one, were belonged to functional class 1. The
follow-up period ranged from 27 days to 158 months. The
clinicopathological features are shown in Table 1. For year
group 1, 12 patients had received postoperative R/T. None
received adjuvant C/T. For year group 2, 21 patients had
received postoperative R/T, three received R/T  C/T. The
C/T regimens included gemcitabine  cisplatin (one patient)
and bleomycin  cisplatin (one patient). The third one was
unknown because the therapy was performed in another
hospital. Two patients received neoadjuvant C/T (all were
Taxol  cisplatin), and five received postoperative C/T. The
regimens included: Taxol  cisplatin (two patients), vinorel-
bine  cisplatin (one patient), gemcitabine  cisplatin (one
patient), and gemcitabine  cisplatin followed by 5FU 
cisplatin (one patient). Totally, there were 10 patients re-
ceived adjuvant or neoadjuvant C/T, and three of the 10
patients had EGFR mutations. For the treatment of TKI, in
year group 1, only one patient with squamous cell carcinoma
(SCC) and no EGFR mutation had received TKI (gefitinib)
treatments for tumor recurrence. For year group 2, 17 pa-
tients, including 14 with ADC, two with SCC, and one with
large cell carcinoma, had received TKI (gefitinib or erlotinib)
for tumor recurrence. Among them, 11 patients (all were
ADC) had EGFR mutations (six were L858R, four were exon
19 deletion, and one was L858R E709G), and one had no
EGFR mutation data. The responsiveness to TKI treatment of
these patients was not evaluated because of complex treat-
ment courses.
The clinicopathological features and genetic markers of
the two year groups of patients were compared (Table 1).
Several demographic variables exhibited significant distribu-
tional difference between the two groups. There were more
male (p 0.0094), more SCC (p 0.0031), and lower EGFR
mutation rate (p  0.0457) in year group 1. The clinicopath-
ological characteristics associated with EGFR mutations is
also analyzed (Table 2). The EGFR mutations were signifi-
cantly associated with female, ADC, nonsmokers, and CISH
() tumor. EGFR mutations were also associated with
younger age (65 years and younger) in this study series (p 
0.0095). We have further divided the patients with EGFR
mutations into three groups: (1) L858R mutation, (2) exon 19
deletions, and (3) other mutations (including all double mu-
tations), because the associated genetic features and the TKI
sensitivity of these mutations were more diverse than single
L858R mutations or exon 19 deletion in our previous studies
and other reports.16,25,29–31 The patterns of all EGFR muta-
tions are shown in Supplement Table 1 (Supplemental Digital
Content 1, http://links.lww.com/JTO/A25).
Survival of Different Year Groups
and Pathology
The major difference in the associated clinicopatholog-
ical characteristics of the two year groups was a decrease of
TABLE 1. Comparison of the Clinical Characteristics of the
164 Patients of the Two Year Groups
Variables
Year Group 1
(1996–1998)
Patients No. (%)
Year Group 2
(2002–2004)
Patients No. (%) p
Gender
Female 15 (21.7) 39 (41.1 0.0094
Male 54 (78.3 56 (59.0)
Age (yr)
65 32 (46.4) 48 (50.5) 0.5997
65 37 (53.6) 47 (49.5)
Diagnosis
ADC 30 (43.5) 67 (70.5) 0.0031a
SCC 33 (47.8) 22 (23.2)
ADSC 2 (2.9) 4 (4.2)
others 4 (5.8) 2 (2.1)
Stageb
I 41 (59.4 48 (50.5) 0.5288
II 9 (13.0) 15 (15.8)
IIIA 19 (27.5) 32 (33.7)
Smoking status
() 31 (56.4) 65 (68.4) 0.1382
() 24 (43.6) 30 (31.6)
CISH
() 21 (70.0) 51 (54.3) 0.1281
() 9 (30.0) 43 (45.7)
KRAS mutations
() 65 (97.0) 84 (94.4) 0.6995a
() 2 (3.0) 5 (5.6
EGFR Mutations
() 53 (76.8) 53 (59.6) 0.0457
() 16 (23.2) 36 (40.4)
a p value from the Fisher’s exact test. The other p values were by 2 tests.
b Pathological stage according to the AJCC staging criteria, sixth edition.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; CISH, chromogenic in situ
hybridization; EGFR, epidermal growth factor receptor; AJCC, American Joint Com-
mittee on Cancer; ADSC, adenosquamous carcinoma.
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SCC and increase of ADC from year group 1 to year group 2
(Table 1). This difference might be largely related to the
sampling procedures (patients agreement or specimen avail-
ability), but it also reflected the trend of a gradual decrease of
SCC and increase of ADC in recent years.32 Because SCC
was more common in male gender and rarely associated with
EGFR mutations, it would result in the statistical differences in
the proportions of gender and EGFR mutations in these two year
groups. To avoid that more SCC than ADC in year group 1
would cause sampling bias for the survival analysis, we have
performed multivariate analyses for suitable adjustment.
Among all of the clinical variables, year group 2 (2002–
2004), younger age (65 years and younger), stage I disease, and
nonsmoker were associated with significant better overall sur-
vival by univariate and multivariate analyses (Table 3 and
Figure 1). The median survival of year group 2 was much longer
than year group 1 (88.6 months versus 21.4 months). These
variables were also associated with significant better
3-year survival. For 5-year survival, only year group, age,
and stage IIIA disease remained to have significant sur-
vival differences. Difference in survival between patients
with SCC and ADC was not significant by univariate analysis
(p  0.2602) but was marginally significant by multivariate
analysis (p  0.0543). We also have performed the same
survival analyses for SCC and ADC, respectively (supple-
ment Table 2 and 3, http://links.lww.com/JTO/A25), and the
prognosticators were quite similar to the data of overall analysis
except smoking status, which was associated with shorter sur-
vival in patients with SCC (p  0.0018) but not in ADC.
Because the survival difference of the two year groups
was quite big, and a larger number of year group 2 patients
had received adjuvant C/T or TKI treatment, we have also
performed survival analysis for the year group 2 patients
only. The 17 patients with TKI treatment were also excluded.
The results still showed similar trends in survival difference
as in the 164 patients, except that the smoking status became
nonsignificant for survival (Table 4).
EGFR Mutations and Survival
When we compared the survival between patients with
or without EGFR mutations, the median survival was much
longer for patient with EGFR mutations (55.5 months) than
wild type (34.9 months), but the difference was not statisti-
cally significant by univariate (p  0.3206) or multivariate
analyses (p  0.1173) (Table 3). If we only compared the
survival of wild-type patients with L858R mutations and
exon 19 deletion only (not including double mutations), the
median survival was also much longer for patient with EGFR
mutations (54.7 months) than wild type (34.9 months). The
difference was still not statistically significant by univariate
analysis (p  0.1981) but had borderline significance by
multivariate analyses (p  0.0506) (Table 3). In addition, the
3-year survival rates of patients with EGFR mutations were
all significantly higher than wild type in both comparisons.
After the 18 patients received TKI treatment were deleted, the
median survival for patients with EGFR mutations and wild
type all became shorter, but the former (52 months) remained
much longer than the latter (30.1 months). When we only
analyzed the EGFR mutations and patient survival of year
group 2 and excluding the 17 patients received TKI treatment
(Table 4), the trend was similar to the whole group. The
median survival of patients with EGFR mutations should still
be longer than wild type (59 months), because it has not been
reached yet.
We also performed the survival analysis for EGFR muta-
tions in the year group 1 patients only. The only one patient
(wild type, SCC), who had received TKI treatment for tumor
recurrence was excluded. In these 68 patients, none received
adjuvant C/T. The median survival of the patients with EGFR
mutations (29.6 months) remained longer than wild type (19.3
months). It was even longer, if only patients with L858R and
exon 19 deletion were included for comparison (49.1 months).
The Log-rank tests and PH regressions appeared nonsignificant
because of hazards crossings (Supplemental Figure 1, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A26).
We have further compared the survival differences
between wild type and the three groups of patients with
EGFR mutations. These three groups of patients all had
longer median survival than wild type (62.4 months for
L858R, 51.9 months for exon 19 deletion, and 56.2 months
for others, respectively), but with no statistic significance by
univariate analyses (Table 6). However, Kaplan-Meier esti-
mates display large discrepancy among different EGFR mu-
tation subgroups (Figure 2A). Only the L858R mutation
TABLE 2. Clinical Characteristics of EGFR Mutation Analyses
in 158 Patients
Variables
EGFR Mutation
() (%)
EGFR Mutation
() (%) pa
Gender
Female 24 (46.2) 28 (53.9) 0.0001
Male 82 (77.4) 24 (22.6)
Age
65 44 (57.1) 33 (42.9) 0.0095
65 62 (76.5) 19 (23.5)
Pathology diagnosis
ADC 43 (46.7) 49 (53.3) 0.0001a
SCC 52 (96.3) 2 (3.7)
ADSC 5 (83.3) 1 (16.7)
others 6 (100) 0 (0)
Stage
I 55 (63.9) 31 (36.1) 0.1967a
II 20 (83.3) 4 (16.7)
IIIA 31 (64.6) 17 (35.4)
Smoking status
() 47 (51.1) 45 (48.9) 0.0001a
() 47 (90.4) 5 (9.6)
CISH
() 61 (88.4) 8 (11.6) 0.0001
() 13 (26.5) 36 (73.5)
KRAS mutations
() 97 (65.1) 52 (34.9) 0.0961a
() 7 (100) 0 (0)
a p value from Fisher’s exact test, the others from 2 test.
ADC, adenocarcinoma; SCC, squamous cell carcinoma; CISH, chromogenic in situ
hybridization; EGFR, epidermal growth factor receptor; ADSC, adenosquamous carcinoma.
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group had significant better overall survival than wild type by
multivariate analyses (p 0.0374). L858R mutation was also
significantly associated with higher 3-year survival rate than
wild type (p  0.0079), but not in 5-year survival (p 
0.3863). This effect became milder, but remained significant,
when the analysis was only restricted to the patients with
ADC (p  0.0452) (Figure 2B). When the 18 TKI-treated
patients were excluded, the median survival becomes shorter
for all mutation groups and wild type, but the trends remained
the same. The L858R group still had higher 3-year survival
than wild type (p  0.0406).
In the case that univariate analysis gave nonsignificant
result, but multivariate analysis gave significant difference,
we need to explain how the confounding structure rendered
these results. By further stratified analyses, we found strong
stratification effects resulted from “age” and “stage” vari-
ables. The older age group (p  0.0211) and stage IIIA
patients (p  0131) both showed significant better survival
TABLE 3. Survival Analyses of 164 Patients with NSCLC
Variables
Death/
Alive
Median Survival
(mo) (95% CI) pa HRb (95% CI) (p) 3-yrc (p) 5-yrd (p)
Year group
1 56/13 21.4 (16.6–44.4) 1.00 0.391 (—) 0.304 (—)
2 47/48 88.6 (43.3–88.6) 0.0011 0.29 (0.15–0.55) (0.0001)e 0.653 (0.0023) 0.526 (0.0080)
Gender
Female 34/20 48.5 (29.5–91.8) 1.00 0.593 (—) 0.444 (—)
Male 69/41 43.9 (28.0–67.9) 0.7218 0.67 (0.33–1.36) (0.2634) 0.518 (0.3527) 0.427 (0.8356)
Age
65 43/37 88.6 (50.1–125.8) 1.00 0.688 (—) 0.523 (—)
65 60/24 23.6 (16.6–39.6) 0.0013 3.97 (2.17–7.26) (.0001)e 0.405 (0.0005) 0.345 (0.0243)
Pathology diagnosisf
ADC 56/41 54.7 (38.0–121.9) 1.00 0.598 (—) 0.463 (—)
SCC 38/17 35.6 (23.5–67.9) 0.2602 0.49 (0.24–1.01) (0.0543) 0.491 (0.2195) 0.400 (0.4606)
Stage
I 46/43 88.6 (49.1–) 1.00 0.674 (—) 0.561 (—)
II 18/6 24.4 (18.0–67.9) 0.0057 2.22 (1.01–4.87) (0.0471) 0.375 (0.0321) 0.333 (0.0859)
IIIA 39/12 23.5 (8.4–45.0) .0001 4.01 (2.07–7.78) (.0001)e 0.392 (0.0042) 0.255 (0.0021)
Smoking statusg
() 55/41 58.0 (40.8–104.7) 1.00 0.635 (—) 0.499 (—)
() 38/16 22.1 (15.6–54.7) 0.0279 1.98 (1.03–3.78) (0.0399) 0.426 (0.0232) 0.352 (0.0984)
CISHg
() 42/30 53.4 (28.7–104.7) 1.00 0.569 (—) 0.471 (—)
() 29/23 56.2 (31.5–) 0.8738 1.14 (0.60–2.14) (0.6948) 0.615 (0.6049) 0.481 (0.9124)
KRAS mutationsg
() 94/55 44.4 (29.5–67.4) 1.00 0.544 (—) 0.429 (—)
() 5/2 21.0 (11.4–88.6) 0.5053 0.88 (0.31–2.45) (0.8015) 0.429 (0.5913) 0.429 (0.9990)
EGFR mutation sg
Wt 69/37 34.9 (23.2–67.9) 1.00 0.491 (—) 0.424 (—)
Mut-1 31/21 55.5 (39.6–) 0.3206 0.53 (0.24–1.17) (0.1173) 0.654 (0.0426) 0.442 (0.8291)
Wt 61/37 34.9 (23.2–67.9) 1.00 0.491 (—) 0.424 (—)
Mut-2 23/18 54.7 (39.6–) 0.1981 0.43 (0.18–1.00) (0.0506) 0.683 (0.0232) 0.488 (0.4733)
EGFR mutationh
Wt 66/34 30.1 (21.0–58.0) 1.00 0.470 (—) 0.400 (—)
Mut-1 26/15 52.0 (29.5–125.8) 0.4732 0.69 (0.28–1.70) (0.4210) 0.585 (0.1952) 0.415 (0.8684)
Wt 66/34 30.1 (21.0–58.0) 1.00 0.470 (—) 0.400 (—)
Mut-2 19/12 52.0 (29.5–) 0.3650 0.53 (0.20–1.42) (0.2052) 0.613 (0.1354) 0.452 (0.5994)
a p value from the log-rank test.
b HR, which is equal to RR estimated, adjusted for other variables using Cox PH model.
c Three-year overall survival rate percentage.
d Five-year overall survival rate percentage.
e Significant under Holm-Bonferroni correction.
f Twelve cases are not included, six with adenosquamous cell carcinoma and six with other carcinomas.
g There are 14, 40, 8, and 6 patients with no data at the smoking status, CISH, KRAS, and EGFR mutation variables, respectively.
h Five patients with no data at the EGFR mutation variable, and 18 patients who had received TKI treatment for tumor recurrence were not included.
NSCLC, non-small cell lung cancer; CI, confidence interval; HR, hazards ratio; RR, relative risk; ADC, adenocarcinoma; SCC, squamous cell carcinoma;
CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor receptor; Wt, wild type; Mut-1, L858R group  exon 19 deletion group others;
Mut-2, L858R group  exon 19 deletion group only; TKI, tyrosine kinase inhibitor.
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for L858R group than wild type (Supplemental Figure 2, Sup-
plemental Digital Content 2, http://links.lww.com/JTO/A27).
This specific effect was lower, when the 12 TKI-treated
patients (six had L858R and six were wild type) were not
included, but the trends were still all the same. However, the
difference became statistically nonsignificant mainly due to
small case numbers (Supplemental Figure 3, Supplemental
Digital Content 3, http://links.lww.com/JTO/A28).
Survival Analyses for KRAS Mutations and EGFR
Gene Copy Number
Patients with KRAS mutations had a shorter median
survival (21 months) than wild-type patients (44.4 months).
However, the difference was not significant statistically. If
only year group 2 patients were analyzed, this trend no longer
existed (Table 4).
For EGFR gene copy number analyses, CISH ()
patients (5 copies per nucleus) also had a longer survival
(56.2 months) than CISH () patients (53.4 months). But the
difference was quite small and was not significant statisti-
cally. If only year group 2 patients were analyzed, this trend
also no longer existed (Table 4).
DISCUSSION
In this study, we have demonstrated that patients with
EGFR mutations had significant higher 3-year survival rates,
and much longer median survival (55.5 months) than wild
type (34.9 months). If we performed the survival analysis
only in the year group 1 patients with no adjuvant C/T and no
TKI treatment, the median survival of the patients with EGFR
mutations remained much longer than wild type (Table 5, and
Supplement Figure 1). Our study is the first one to demon-
strate the differences of median survival between patients
with or without EGFR mutations in patients with surgically
resectable NSCLC. All previous reports had only overall
survival data due to limitation of follow-up time.14,20–22,25
When we further divided the mutations into three
groups, the median survivals (62.4 months for L858R, 51.9
months for exon 19 deletion, and 56.2 months for others,
respectively) were all longer than wild type. Interestingly, the
median survival and 3-year survival rate of the L858R group
were all better than exon 19 deletion group (Table 6). This
result was similar to the report of Shigematsu et al.,20 which
also found that L858R had the best overall survival and the
exon 19 deletion had the worst, even shorter than the wild
type (the difference was nonsignificant statistically). After the
patients treated by TKI were excluded, the median survival
and 3-year survival rate of L858R mutation group remained
to be the best. This survival data was quite different from the
studies on patients with advanced-stage NSCLC treated by
TKIs, which usually showed higher TKI response rate or a
FIGURE 1. Kaplan-Meier curves for overall survival of 164 patients with non-small cell lung cancer for A, Year group 1 versus
year group 2; B, Younger age (65 years and younger) versus older age (65 years or older); C, Stages I, II, and IIIA; and D, non-
smoker versus ever-smoker. These four variables all were associated with significant survival differences.
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longer survival for patients with exon 19 deletion than
L858R.29,33,34 The underlying mechanism will need further
investigations.
In this study, the patients of year group 2 showed
significant better overall survival than year group 1 by uni-
variate and multivariate analyses. This improvement in sur-
vival could involve multiple factors, including improved
socioeconomic status and better supportive care, etc. Among
them, the improvement of systemic C/T, such as third gen-
eration chemotherapeutic agents (gemcitabine, paclitaxel, do-
cetaxel, and vinorelbine) for NSCLC might have played some
roles.35,36 These new chemotherapeutic agents became reim-
bursed by the National Health Insurance and were more
widely used in Taiwan after 1999. Therefore, most of the year
group 1 patients, especially stage II and stage IIIA, would
have fewer chances to be treated by these new reagents than
year group 2. This could also explain why there were 10
patients in year group 2 received adjuvant C/T but none in
year group 1.
It is puzzling to find that patients with NSCLC with
EGFR mutation had better survival than wild type, because
EGFR-over expressed malignant tumors arising from other
major organs, such as breast, colon, and head and neck
cancers were usually associated with poor prognosis and
decreased survival.37–39 The underlying mechanism of this
survival difference is not clear at this point. It is possible that
EGFR mutants have provided full spectrum of growth advan-
tage because of their constitutive activation status. Therefore,
those EGFR mutation-harboring cancer cells were not re-
quired to obtain many other mutations that either promote
survival or prevent cell death during their developmental
process. Because EGFR KD mutations rarely occur in other
types of epithelial cancers, the presence of EGFR KD muta-
tions might be less favorable for the progression of these
TABLE 4. Survival Analyses of 73 Patients with NSCLC without TKI Treatment in Year Group 2 (2002–2004)
Variables
Death/
Alive
Median Survival
(mo) (95% CI) pa HRb (95% CI) (p) 3-yrc (p) 5-yrd (p)
Gender
Female 15/13 48.5 (29.5–) 0.571 (—) 0.464 (—)
Male 22/23 67.9 (39.6–) 0.6216 1.01 (0.43–2.39) (0.9783) 0.644 (0.5429) 0.532 (0.5792)
Age
65 12/21 — (56.2–) 0.758 (—) 0.634 (—)
65 25/15 37.0 (23.2–) 0.0140 4.31 (1.83–10.16) (0.0008)e 0.500 (0.0255) 0.400 (0.0500)
Pathology diagnosis
ADC 24/25 — (31.5–) 0.633 (—) 0.509 (—)
SCC 10/9 67.9 (34.3–) 0.9901 0.40 (0.13–1.23) (0.1092) 0.632 (0.9939) 0.526 (0.8991)
others 3/2 20.7 (3.4–) 0.3319 0.85 (0.20–3.58) (0.8288) 0.400 (0.4111) 0.400 (0.6700)
Stage
I 12/23 — (50.1–) 0.800 (—) 0.657 (—)
II 9/5 36.1 (20.7–) 0.0282 4.36 (1.53–12.41) (0.0058)e 0.500 (0.0935) 0.429 (0.1988)
IIIA 16/8 28.2 (8.0–) 0.0028 6.72 (2.42–18.62) (0.0003)e 0.417 (0.0108) 0.333 (0.0303)
Smoking statusf
() 23/25 — (39.6–) 0.646 (—) 0.519 (—)
() 14/11 — (35.6–) 0.5028 1.86 (0.76–4.56) (0.1746) 0.560 (0.4901) 0.480 (0.7551)
CISH
0 19/22 — (35.6–) 0.634 (—) 0.561 (—)
1 18/13 43.3 (28.5–) 0.3183 0.73 (0.23–2.34) (0.5942) 0.581 (0.6514) 0.419 (0.2479)
KRAS
0 35/34 67.9 (39.6–) 0.623 (—) 0.506 (—)
1 2/2 — (4.3–) 0.7750 0.85 (0.16–4.51) (0.8522) 0.500 (0.6655) 0.500 (0.9815)
EGFR mutation
Wt 25/23 59.0 (29.5–) 1.00 0.583 (—) 0.500 (—)
Mut-1 12/13 — (31.5–) 0.6211 0.69 (0.23–2.09) (0.5153) 0.680 (0.4021) 0.520 (0.8704)
Wt 25/23 59.0 (29.5–) 1.00 0.583 (—) 0.500 (—)
Mut-2 8/10 — (31.5–) 0.5415 0.63 (0.20–1.91) (0.4097) 0.667 (0.5146) 0.556 (0.6776)
a p value from the log-rank test.
b HR, which is equal to RR estimated, adjusted for other variables using Cox PH model.
c Three-year overall survival rate percentage.
d Five-year overall survival rate percentage.
e Significant under Holm-Bonferroni correction.
f There are four patients with no data at the smoking status.
NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; CI, confidence interval; HR, hazards ratio; RR, relative risk; ADC, adenocarcinoma;
SCC, squamous cell carcinoma; CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor receptor; Wt, wild type; Mut-1, L858R group 
exon 19 deletion group others; Mut-2, L858R group  exon 19 deletion group only.
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epithelial cancers in tissues other than lung. The above
hypothesis could explain the higher susceptibility to antican-
cer treatment, such as C/T or R/T, for patients with advanced-
staged NSCLC with EGFR mutations.17,18,40
For other genetic markers, KRAS mutations have been
associated with shorter survival irrespective of therapeutic
regimens by various studies from Asia or western coun-
tries.41,42 In this study, patients with KRAS mutations also had
FIGURE 2. Kaplan-Meier curves for overall survival of wild type versus three groups of EGFR mutations: L858R, exon 19 deletion,
and others, respectively. The p values of multivariate analyses were shown. A, A total of 158 patients with non-small cell lung can-
cer. B, Ninety-two patients with adenocarcinoma. Only L858R group was significantly better than wild type by multivariate analysis.
TABLE 5. Survival Analyses of EGFR Mutations in 68 Patients with NSCLC in Year Group 1 (1996–1998)a
Variables
Death/
Alive
Median Survival
(mo) (95% CI) pb HRc (95% CI) (p) 3-yrd (p) 5-yre (p)
EGFR mutation
Wt 41/11 19.3 (15.2–30.8) 1.00 0.365 (—) 0.308 (—)
Mut-1 14/2 29.6 (17.6–54.7) 0.8563 5.93 (0.47–75.4) (0.1702) 0.438 (0.5886) 0.250 (0.6641)
Wt 41/11 19.3 (15.2–30.8) 1.00 0.365 (—) 0.308 (—)
Mut-2 11/2 49.1 (21.0–62.4) 0.6163 0.04 (0.01–8.9) (0.2439) 0.539 (0.2161) 0.308 (0.9999)
a One patient who had received TKI treatment was excluded.
b p value from the log-rank test.
c HR, which is equal to RR estimated, adjusted for other variables using Cox PH model.
d Three-year overall survival rate percentage.
e Five-year overall survival rate percentage.
EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; CI, confidence interval; HR, hazards ratio; RR, relative risk; Wt, wild type;
Mut-1, L858R group  exon 19 deletion group others; Mut-2, L858R group  exon 19 deletion group only; TKI, tyrosine kinase inhibitor.
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shorter median survival (21 months) than those with wild
type (44.4 months), but the difference could not reach statis-
tical significance. It is most likely due to the very low KRAS
mutation rate (7 of 164, 4.3%) in our patients with NSCLC in
this study and in our previous report.27
For the EGFR gene copy numbers and survival, CISH
study was performed. CISH examination was the same as
fluorescence in situ hybridization (FISH) except the detection
method. The former used chromogen and the latter used
fluorescence. Good correlations between CISH and FISH
examination have been reported by multiple research cen-
ters.43–45 This study demonstrated that CISH () patients
(EGFR polysomy) had a longer survival (56.2 months) than
CISH () patients (53.4 months). But the difference was
much smaller than in EGFR mutations and was not significant
statistically. It is similar to our previous study for EGFR gene
copy numbers and TKI response.26 We also demonstrated that
tumors with EGFR polysomy were strongly associated with
EGFR mutations, but the correlation with TKI response had
only borderline significance (p  0.0665). Only EGFR mu-
tations were significantly associated with TKI response (p 
0.0001). The above findings suggested that the association of
EGFR polysomy with TKI responses or longer median survival
might be all driven by the overlap of high EGFR gene copy
number with a positive EGFR mutation status. A recent pub-
lished clinical trial (IPASS) for only Asian patients with NSCLC
also made similar conclusions about EGFR polysomy (by FISH
study) and TKI responsiveness.18 But this association might not
be the same in patients with NSCLC of western countries,
because several reports have demonstrated that patients with
NSCLC with EGFR polysomy (FISH positive) were signifi-
cantly associated with TKI response in western countries.46,47
The better survival associated with EGFR mutations
shown in this study would pose new insight to the mechanism
of cancer progression. For such a tumor biology, in the future
clinical trials for adjuvant therapy in patients with NSCLC, a
stratification by EGFR mutation may be necessary to avoid an
uneven distribution of the EGFR mutation that may confound
the final survival data.
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